King Keytruda: Merck's PD-1 star scores #1 position and $22B+ prediction in another top 10 blockbuster list for 2025
Predicting which of the current blockbusters will ascend to new heights is anyone’s game, and one that highlights the current dynamics of the industry. On Friday it’s GlobalData’s turn to pick out the therapies that it believes will come out on top in some intensely competitive spaces.
Humira may still top the chart for best-selling drugs in the world, but Keytruda is set to overtake the shrinking franchise in around five years time — with four other drugs set to get ahead of AbbVie’s biggest cash cow.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.